Salt Transiently Inhibits Mitochondrial Energetics in Mononuclear Phagocytes.


Journal

Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763

Informations de publication

Date de publication:
13 07 2021
Historique:
pubmed: 29 4 2021
medline: 30 12 2021
entrez: 28 4 2021
Statut: ppublish

Résumé

Dietary high salt (HS) is a leading risk factor for mortality and morbidity. Serum sodium transiently increases postprandially but can also accumulate at sites of inflammation affecting differentiation and function of innate and adaptive immune cells. Here, we focus on how changes in extracellular sodium, mimicking alterations in the circulation and tissues, affect the early metabolic, transcriptional, and functional adaption of human and murine mononuclear phagocytes. Using Seahorse technology, pulsed stable isotope-resolved metabolomics, and enzyme activity assays, we characterize the central carbon metabolism and mitochondrial function of human and murine mononuclear phagocytes under HS in vitro. HS as well as pharmacological uncoupling of the electron transport chain under normal salt is used to analyze mitochondrial function on immune cell activation and function (as determined by Extracellular sodium was taken up into the intracellular compartment, followed by the inhibition of mitochondrial respiration in murine and human macrophages. Mechanistically, HS reduces mitochondrial membrane potential, electron transport chain complex II activity, oxygen consumption, and ATP production independently of the polarization status of macrophages. Subsequently, cell activation is altered with improved bactericidal function in HS-treated M1-like macrophages and diminished CD4 Our data identify the disturbance of mitochondrial respiration as the initial step by which HS mechanistically influences immune cell function. Although these functional changes might help to resolve bacterial infections, a shift toward proinflammation could accelerate inflammatory cardiovascular disease.

Sections du résumé

BACKGROUND
Dietary high salt (HS) is a leading risk factor for mortality and morbidity. Serum sodium transiently increases postprandially but can also accumulate at sites of inflammation affecting differentiation and function of innate and adaptive immune cells. Here, we focus on how changes in extracellular sodium, mimicking alterations in the circulation and tissues, affect the early metabolic, transcriptional, and functional adaption of human and murine mononuclear phagocytes.
METHODS
Using Seahorse technology, pulsed stable isotope-resolved metabolomics, and enzyme activity assays, we characterize the central carbon metabolism and mitochondrial function of human and murine mononuclear phagocytes under HS in vitro. HS as well as pharmacological uncoupling of the electron transport chain under normal salt is used to analyze mitochondrial function on immune cell activation and function (as determined by
RESULTS
Extracellular sodium was taken up into the intracellular compartment, followed by the inhibition of mitochondrial respiration in murine and human macrophages. Mechanistically, HS reduces mitochondrial membrane potential, electron transport chain complex II activity, oxygen consumption, and ATP production independently of the polarization status of macrophages. Subsequently, cell activation is altered with improved bactericidal function in HS-treated M1-like macrophages and diminished CD4
CONCLUSIONS
Our data identify the disturbance of mitochondrial respiration as the initial step by which HS mechanistically influences immune cell function. Although these functional changes might help to resolve bacterial infections, a shift toward proinflammation could accelerate inflammatory cardiovascular disease.

Identifiants

pubmed: 33906377
doi: 10.1161/CIRCULATIONAHA.120.052788
pmc: PMC8270232
doi:

Substances chimiques

Sodium Chloride, Dietary 0

Banques de données

ClinicalTrials.gov
['NCT02509962', 'NCT04175249']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

144-158

Commentaires et corrections

Type : ErratumIn

Références

Nat Rev Immunol. 2019 Apr;19(4):243-254
pubmed: 30644452
Nat Med. 2018 Jun;24(6):711-720
pubmed: 29867229
Eur Heart J. 2013 Jul;34(28):2108-9
pubmed: 24040671
J Clin Invest. 2015 Nov 2;125(11):4212-22
pubmed: 26524592
Kidney Int. 2012 Feb;81(4):407-11
pubmed: 22048126
Cell Metab. 2015 Mar 3;21(3):493-501
pubmed: 25738463
Circulation. 2019 Oct 01;140(14):1205-1216
pubmed: 31769940
Immunol Rev. 2020 May;295(1):54-67
pubmed: 32242952
Nature. 2017 Nov 30;551(7682):585-589
pubmed: 29143823
Biol Pharm Bull. 2012;35(10):1661-8
pubmed: 23037156
Atherosclerosis. 2014 Jan;232(1):211-6
pubmed: 24401240
Cell Res. 2015 Aug;25(8):893-910
pubmed: 26206316
Hypertension. 2012 Jan;59(1):167-72
pubmed: 22146510
Immunity. 2015 Mar 17;42(3):419-30
pubmed: 25786174
Sci Rep. 2016 Oct 24;6:35855
pubmed: 27775051
Lancet. 2019 May 11;393(10184):1958-1972
pubmed: 30954305
Oncotarget. 2017 Jan 3;8(1):70-82
pubmed: 27926535
Cell Metab. 2019 Aug 6;30(2):352-363.e8
pubmed: 31130465
PLoS One. 2015 Oct 26;10(10):e0141336
pubmed: 26501774
Immunity. 2018 Dec 18;49(6):1021-1033.e6
pubmed: 30566880
J Am Soc Nephrol. 2015 Oct;26(10):2341-7
pubmed: 25833841
Circ Res. 2018 May 11;122(10):1460-1478
pubmed: 29748369
Pediatr Cardiol. 2011 Mar;32(3):267-74
pubmed: 21210091
Immunity. 2016 Oct 18;45(4):817-830
pubmed: 27760338
Cardiovasc Diabetol. 2018 Jan 4;17(1):5
pubmed: 29301520
Brain. 2013 Jul;136(Pt 7):2305-17
pubmed: 23801742
Nat Commun. 2015 May 11;6:6931
pubmed: 25959047
Nat Immunol. 2019 Jul;20(7):793-801
pubmed: 31213715
J Clin Invest. 2015 Nov 2;125(11):4223-38
pubmed: 26485286
N Engl J Med. 2014 Aug 14;371(7):624-34
pubmed: 25119608
Diabetologia. 2017 Mar;60(3):568-573
pubmed: 27752710
Nature. 2020 Oct;586(7828):287-291
pubmed: 32728214
Nature. 1965 Dec 18;208(5016):1205-6
pubmed: 5870319
Kidney Int. 2015 Feb;87(2):434-41
pubmed: 25100048
Cell Metab. 2016 Jul 12;24(1):158-66
pubmed: 27374498
Immunity. 2014 Feb 20;40(2):274-88
pubmed: 24530056
J Clin Invest. 2017 May 1;127(5):1944-1959
pubmed: 28414295
Metabolites. 2020 Nov 12;10(11):
pubmed: 33198249
PLoS Biol. 2020 Jun 22;18(6):e3000722
pubmed: 32569301
Nature. 2013 Jan 17;493(7432):346-55
pubmed: 23325217
Hypertension. 2013 Mar;61(3):635-40
pubmed: 23339169
Front Bioeng Biotechnol. 2015 Jan 21;2:84
pubmed: 25654076
J Am Coll Cardiol. 2020 Feb 4;75(4):422-434
pubmed: 32000955
Autophagy. 2019 Nov;15(11):1899-1916
pubmed: 30982460
Nature. 2013 Apr 25;496(7446):518-22
pubmed: 23467095
Cancer Metab. 2014 Jun 30;2:9
pubmed: 25035808
Kidney Int. 2019 Feb;95(2):296-309
pubmed: 30665570
Nature. 2013 Apr 25;496(7446):513-7
pubmed: 23467085
J Autoimmun. 2016 Feb;67:90-101
pubmed: 26584738
Cell. 2016 Oct 6;167(2):457-470.e13
pubmed: 27667687

Auteurs

Sabrina Geisberger (S)

Experimental and Clinical Research Center, a joint cooperation of Max-Delbrück-Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).
Integrative Proteomics and Metabolomics, Berlin Institute for Medical Systems Biology, Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Germany (S.G., C.Z., S.K.).
German Center for Cardiovascular Research, partner site Berlin (S.G., H.B., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).
Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).

Hendrik Bartolomaeus (H)

Experimental and Clinical Research Center, a joint cooperation of Max-Delbrück-Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).
German Center for Cardiovascular Research, partner site Berlin (S.G., H.B., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).
Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (H.B., V.M., A. Maifeld, A. Mähler, L.M., S.K.F., R.D., D.N.M.).
Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).

Patrick Neubert (P)

Institute of Clinical Microbiology and Hygiene, University Hospital of Regensburg, University of Regensburg, Germany (P.N., L.K., M.V., J.J.).

Ralf Willebrand (R)

VIB Laboratory of Translational Immunomodulation, VIB Center for Inflammation Research, UHasselt, Campus Diepenbeek, Belgium (R.W., D.S., A.G., M.K.).

Christin Zasada (C)

Integrative Proteomics and Metabolomics, Berlin Institute for Medical Systems Biology, Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Germany (S.G., C.Z., S.K.).

Thomas Bartolomaeus (T)

Institute of Evolutionary Biology, University of Bonn, Germany (T.B., E.T.).

Victoria McParland (V)

Experimental and Clinical Research Center, a joint cooperation of Max-Delbrück-Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).
Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (H.B., V.M., A. Maifeld, A. Mähler, L.M., S.K.F., R.D., D.N.M.).
Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).

Dries Swinnen (D)

VIB Laboratory of Translational Immunomodulation, VIB Center for Inflammation Research, UHasselt, Campus Diepenbeek, Belgium (R.W., D.S., A.G., M.K.).

Anneleen Geuzens (A)

VIB Laboratory of Translational Immunomodulation, VIB Center for Inflammation Research, UHasselt, Campus Diepenbeek, Belgium (R.W., D.S., A.G., M.K.).

András Maifeld (A)

Experimental and Clinical Research Center, a joint cooperation of Max-Delbrück-Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).
Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (H.B., V.M., A. Maifeld, A. Mähler, L.M., S.K.F., R.D., D.N.M.).
Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).

Luka Krampert (L)

Institute of Clinical Microbiology and Hygiene, University Hospital of Regensburg, University of Regensburg, Germany (P.N., L.K., M.V., J.J.).

Marion Vogl (M)

Institute of Clinical Microbiology and Hygiene, University Hospital of Regensburg, University of Regensburg, Germany (P.N., L.K., M.V., J.J.).

Anja Mähler (A)

Experimental and Clinical Research Center, a joint cooperation of Max-Delbrück-Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).
German Center for Cardiovascular Research, partner site Berlin (S.G., H.B., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).
Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (H.B., V.M., A. Maifeld, A. Mähler, L.M., S.K.F., R.D., D.N.M.).
Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).

Nicola Wilck (N)

Experimental and Clinical Research Center, a joint cooperation of Max-Delbrück-Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).
German Center for Cardiovascular Research, partner site Berlin (S.G., H.B., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).
Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Germany (N.W.).
Department of Nephrology and Internal Intensive Care Medicine (N.W.).
Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).

Lajos Markó (L)

Experimental and Clinical Research Center, a joint cooperation of Max-Delbrück-Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).
German Center for Cardiovascular Research, partner site Berlin (S.G., H.B., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).
Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (H.B., V.M., A. Maifeld, A. Mähler, L.M., S.K.F., R.D., D.N.M.).
Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).

Ekin Tilic (E)

Institute of Evolutionary Biology, University of Bonn, Germany (T.B., E.T.).

Sofia K Forslund (SK)

Experimental and Clinical Research Center, a joint cooperation of Max-Delbrück-Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).
German Center for Cardiovascular Research, partner site Berlin (S.G., H.B., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).
Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (H.B., V.M., A. Maifeld, A. Mähler, L.M., S.K.F., R.D., D.N.M.).
Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).

Katrina J Binger (KJ)

Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Australia (K.J.B.).

Johannes Stegbauer (J)

Department of Nephrology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Germany (J.S.).

Ralf Dechend (R)

Experimental and Clinical Research Center, a joint cooperation of Max-Delbrück-Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).
German Center for Cardiovascular Research, partner site Berlin (S.G., H.B., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).
Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (H.B., V.M., A. Maifeld, A. Mähler, L.M., S.K.F., R.D., D.N.M.).
Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).
Department of Cardiology and Nephrology, HELIOS-Klinikum, Berlin, Germany (R.D.).

Markus Kleinewietfeld (M)

VIB Laboratory of Translational Immunomodulation, VIB Center for Inflammation Research, UHasselt, Campus Diepenbeek, Belgium (R.W., D.S., A.G., M.K.).

Jonathan Jantsch (J)

Institute of Clinical Microbiology and Hygiene, University Hospital of Regensburg, University of Regensburg, Germany (P.N., L.K., M.V., J.J.).

Stefan Kempa (S)

Integrative Proteomics and Metabolomics, Berlin Institute for Medical Systems Biology, Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Germany (S.G., C.Z., S.K.).

Dominik N Müller (DN)

Experimental and Clinical Research Center, a joint cooperation of Max-Delbrück-Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).
German Center for Cardiovascular Research, partner site Berlin (S.G., H.B., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).
Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (H.B., V.M., A. Maifeld, A. Mähler, L.M., S.K.F., R.D., D.N.M.).
Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (S.G., H.B., V.M., A. Maifeld, A. Mähler, N.W., L.M., S.K.F., R.D., D.N.M.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH